Belite Bio Inc ADR (BLTE)

$59.68 -4.54 (-7.07%)
Market Cap 2.04B
Revenue (ttm) 0.00
Net Income (ttm) -36.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,400
Avg Vol 33,250
Day's Range N/A - N/A
Shares Out 31.84M
Stochastic %K 0%
Beta -1.44
Analysts Strong Sell
Price Target $85.00

Latest News on BLTE

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

May 21, 2025, 3:00 AM EDT - 17 days ago

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

May 15, 2025, 11:53 AM EDT - 22 days ago

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:59 AM EDT - 23 days ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:00 PM EDT - 24 days ago

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

May 12, 2025, 8:35 AM EDT - 25 days ago

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

Belite Bio to Participate in Four Upcoming Investor Conferences

May 12, 2025, 8:00 AM EDT - 25 days ago

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:40 PM EDT - 2 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 17, 2025, 6:00 AM EDT - 2 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 17, 2025, 6:00 AM EDT - 2 months ago

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 3:00 AM EDT - 3 months ago

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Belite Bio Announces Registered Direct Offering of $15 Million

Feb 5, 2025, 10:35 PM EST - 4 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Nov 27, 2024, 3:00 AM EST - 6 months ago

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:28 PM EST - 7 months ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Nov 5, 2024, 8:00 AM EST - 7 months ago

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Nov 3, 2024, 4:00 PM EST - 7 months ago

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Sep 1, 2024, 8:00 AM EDT - 9 months ago

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 10:35 PM EDT - 10 months ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 9, 2024, 4:30 PM EDT - 10 months ago

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 8:00 AM EDT - 10 months ago

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Aug 5, 2024, 7:10 PM EDT - 10 months ago

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Jun 12, 2024, 2:55 AM EDT - 1 year ago

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 9:50 PM EDT - 1 year ago

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 6, 2024, 8:15 AM EDT - 1 year ago

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 6, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 1, 2024, 4:15 PM EDT - 1 year ago

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Belite Bio Announces $25 Million Registered Direct Offering

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:53 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 11, 2024, 10:28 PM EDT - 1 year ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 9:27 PM EDT - 1 year ago

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 20, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Participate in the BTIG Ophthalmology Day

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 11:30 PM EST - 1 year ago

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 13, 2023, 8:15 PM EST - 1 year ago

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Nov 7, 2023, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Nov 6, 2023, 8:00 AM EST - 1 year ago

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

Aug 22, 2023, 3:51 PM EDT - 1 year ago

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Aug 13, 2023, 9:45 AM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 8, 2023, 10:17 PM EDT - 1 year ago

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Aug 4, 2023, 8:00 AM EDT - 2 years ago

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Jul 27, 2023, 5:00 PM EDT - 2 years ago

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Jul 24, 2023, 6:04 AM EDT - 2 years ago

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease